Nektar upgraded at Oppenheimer on upcoming mid-stage trial readout
Nektar Therapeutics (NKTR) stock surges as Oppenheimer upgrades ahead of key mid-stage trial readout for an eczema drug. Read ...
Zacks.com on MSN15h
Nektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised)
Nektar (NKTR) delivered earnings and revenue surprises of -15.38% and 25.23%, respectively, for the quarter ended December ...
Nektar Therapeutics (NASDAQ:NKTR) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript March 12, 2025 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.15 ...
Nektar Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
Full Year 2024 Results Key Financial Results Revenue: US$98.4m (up 9.2% from ...
Healio11h
Patients with unresponsive atopic dermatitis saw improvement with rocatinlimab
Treatment-experienced patients with moderate to severe atopic dermatitis attained higher efficacy rates on rocatinlimab ...
Piper Sandler Reaffirms Their Buy Rating on Altimmune (ALT)
In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Altimmune (ALT – Research Report), with a price target ...
aTyr Pharma (ATYR) Gets a Buy from Piper Sandler
Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on aTyr Pharma (ATYR – Research Report) today and set a price target of $20.00.
12 Health Care Stocks Moving In Friday's Pre-Market Session
Shuttle Pharmaceuticals SHPH stock declined by 25.6% to $0.32 during Friday's pre-market session. The company's market cap stands at $1.5 million. AirSculpt Technologies AIRS shares decreased by 16.33 ...